-The Hindu   Ranbaxy's fraudulent practices may have jeopardised millions of lives in India, Africa and the U.S. Exactly two weeks ago, the pharmaceuticals industry was rocked by revelations that one of the world's largest generic drug manufacturers, Ranbaxy Laboratories, pleaded guilty to seven federal criminal charges stemming from its fraudulent production practices dating back to 2008, and agreed to pay U.S. regulators $500 million in fines. Much has since been said about Ranbaxy's...

-The Economic Times Japanese companies do not mind erring on the side of caution. They are known to think longer and harder than their counterparts in other countries about big decisions, especially when it comes to entering a new market or acquiring a foreign company. But Japan's third biggest drugmaker Daiichi Sankyo would now wish it had spent more time doing due diligence on Ranbaxy Labs, in which it bought a...

-The Business Standard Why government policy and jobless growth have let inequality worsen in recent times The Forbes list of billionaires features 55 Indians in 2013. The estimated net worth of only the top ten is $102.1 billion or approximately 5.5 per cent of India's gross domestic product. Paradoxically, every third poor person and every second malnourished child in the world is also an Indian. India also adds 7.5 million babies with...

-The Hindu New York: Dayamani Barla was presented with the first ever Ellen L. Lutz Indigenous Rights Award by Cultural Survival, an indigenous peoples' rights organisation The Big Apple is renowned as the home of investment banks, glitzy fashion shows and other 21st-century tributes to prodigious wealth accumulation. But on Thursday it played host to a powerful symbol of Indian adivasis' struggle against oppression, Jharkhand activist and journalist Dayamani Barla. On a rainy...

-The Business Standard The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals. Last week, Ranbaxy had agreed to...